2023 World Conference on Lung Cancer (Posters)-EP11.03. Molecular Characterization and Prognosis of Patients with KRAS Mutant Non-small Cell Lung Cancer

EP11.03. Molecular Characterization and Prognosis of Patients with KRAS Mutant Non-small Cell Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

In this study, the authors aimed to molecularly characterize and determine the prognosis of patients with KRAS mutant non-small cell lung cancer (NSCLC). They conducted a retrospective analysis of patients with KRAS mutant NSCLC diagnosed at La Paz University Hospital from May 2022 to March 2023. The patients' KRAS status was determined using next-generation sequencing (NGS) and PD-L1 expression was analyzed by immunohistochemistry.<br /><br />Out of 222 patients analyzed, 49 patients (22%) had KRAS mutations. The majority of these patients were males with a median age of 67 years old and a smoking history. The most common histology observed was adenocarcinoma. Regarding the stage at diagnosis, most patients had stage IV (51%), followed by stage III (14.3%), stage II (8.2%), and stage I (26.5%). Over 40% of the patients had PD-L1 expression of 50% or higher.<br /><br />The most frequent KRAS mutation found was G12C, followed by G12V and G12D. A significant proportion of patients had co-mutations, with TP53 and CDKN2A being the most common. Patients with stage I and II underwent surgery, while those with stage IIIA received chemoradiation. Disease relapse was observed in some patients, with a relapse-free survival of 28 months.<br /><br />For patients with advanced disease, the majority received chemoimmunotherapy, and they achieved a partial response after first-line treatment. The progression-free survival (PFS) for patients who received first-line treatment was 16.8 months, and the overall survival (OS) for all patients with advanced disease was 9.9 months.<br /><br />In conclusion, the study found that KRAS G12C was the most frequent mutation in patients with KRAS mutant NSCLC. The authors observed a high response rate and a long PFS in patients treated with chemoimmunotherapy or immunotherapy. However, further prospective studies are needed to confirm these findings.

Asset Subtitle

Laura Gutiérrez Sainz

Meta Tag

Speaker Laura Gutiérrez Sainz

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

KRAS mutant NSCLC

molecular characterization

prognosis

retrospective analysis

next-generation sequencing

PD-L1 expression

adenocarcinoma

KRAS mutations

chemoimmunotherapy

prospective studies